The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: Results from a randomized controlled trial (SURF trial)
File Type:
PDFItem Type:
Journal ArticleDate:
2016Access:
openAccessCitation:
Phoa K.N, Rosmolen W.D, Weusten B.L.A.M, Bisschops R, Schoon E.J, Das S, Ragunath K, Fullarton G, DiPietro M, Ravi N, Tijssen J.G.P, Dijkgraaf M.G.W, Bergman J.J.G.H.M, The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: Results from a randomized controlled trial (SURF trial), Gastrointestinal Endoscopy, 2016, 1--Download Item:
Abstract:
Background and Aims
The Surveillance versus Radiofrequency Ablation (SURF) trial randomized 136 patients with Barrett's esophagus (BE) containing low-grade dysplasia (LGD), to receive radiofrequency ablation (ablation, n = 68) or endoscopic surveillance (control, n = 68). Ablation reduced the risk of neoplastic progression to high-grade dysplasia and esophageal adenocarcinoma (EAC) by 25% over 3 years (1.5% for ablation vs 26.5% for control). We performed a cost-effectiveness analysis from a provider perspective alongside this trial.
Author's Homepage:
http://people.tcd.ie/ravinDescription:
IN_PRESS
Author: RAVI, NARAYANASAMY
Type of material:
Journal ArticleCollections
Series/Report no:
Gastrointestinal EndoscopyAvailability:
Full text availableDOI:
http://dx.doi.org/10.1016/j.gie.2016.12.001Metadata
Show full item recordThe following license files are associated with this item: